| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8227832 | International Journal of Radiation Oncology*Biology*Physics | 2012 | 6 Pages |
Abstract
Along with an increase in median progression-free survival, bevacizumab therapy increased the risk of DIR in HGG patients. The risk of increased invasion with prolonged angiogenic blockade should be addressed in future clinical trials.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Ashwatha M.D., Saroj D. M.S., Praveen M.P.H., John M.D., Erik M.D., Edmond M.D., David M.D., Patricia R.N., Deborah M.D., Michael L. M.D.,